14. Anker SD, Coats AJS, Roecker EB et al. Does carvedilol prevent and reverse cardia cachexia in patients with severe heart failure? Results of the COPERNICUS study // Europ. Heart J. – 2002. – Vol. 4 (Suppl. Abstr.): 394.
15. Barzilay JI, Pressel S, Davis BR, et al, for the ALLHAT Collaborative Research Group. Risk and impact of incident glucose disorders in hypertensive older adults treated with an ACE inhibitor, a diuretic, or a calcium channel blocker: a report fromthe ALLHAT trial. Am J Hyp ertens. 2004;17(5, part 2 of 2):1A.
16. Bristow MR, Abraham WT, Gilbert EM et al. Relationships between carvedilol stereoisomer plasma concentrations and b-receptor occupancies in subjects with chronic heart failure in the Multicenter Oral Carvedilol Heart Failure Assessment (MOCHA) trial // XVIII Congress of ESC (Aug. 25-29, Birmingham). – 1996. – Аbstr. № 802.
17. Cheitlin MD, Alpert JS, Armstrong WF, et al: ACC/AHA Guidelines for the CIBIS-II Investigators and Commitees. The Cardiac Insuffiency Bisoprolol Study II (CIBIS-II): a randomised trial // Lancet. – 1999. – Vol. 353: 9-13.
18. Bristow M, Saxon L, Boehmer J et al. Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac–resynchrozation therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150.
19. Bonow RO, Carabello B, de Leon AC Jr et al. Guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). Circulation. 1998;98:1949–1984.
20. Captopril Multicenter Research Group. A placebo–controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol. 1983;2:755–63.
21. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52.
22. Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in coll. Circulation 1997 Mar 18; 95(6): 1686-744.
23. Chidsey CA, Harrison DC, Braunwald E, Mason DT: Augmentation of plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962; 267: 650.
24. Chronic heart failure: management of chronic heart failure in adults in primary and secondary Care. Clinical guideline. National Institute for Health and Clinical Excellence Compilation. Issue date – July 2003 Review date – July 2007 http://guidance.nice.org.uk/CG5
25. CIBIS Investigators and Committees: A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994 Oct; 90(4): 1765-73.
26. CIBIS III trial: bisoprolol treatment for CHF leads to 46% reduction in sudden death after one year. Cardiovasc J S Afr. 2006;17(5):278.
27. Cleland JGF. The perindopril in elderly people with chronic heart failure (PEP–CHF) study. Hot Line I Session on XVth World Congress of Cardiology, Barcelona, 03 September 2006.
28. Cleland JG, Coletta AP, Lammiman M et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE–HF extension study, ESSENTIAL, CIBIS–III, S–ICD, ISSUE–2, STRIDE–2, SOFA, IMAGINE, PREAMI, SIRIUS–II and ACTIVE. Eur J Heart Fail. 2005;7(6):1070–5.
29. Cody RJ: Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. J Am Coll Cardiol 1993 Oct; 22(4 Suppl A): 165A-171A.
30. Cohn JN, Archibald DG, Ziesche S, et al: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986 Jun 12; 314(24): 1547-52.
31. Cohn JN, Ziesche S, Smith R, et al: Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997 Aug 5; 96(3): 856-63.
32. Coletta AP. COMPANION: the comparison of medical therapy, pacing and defibrillation in chronic heart failure trial // Europ. J. Heart Failure. – 2003. – Vol. 5: 95-99.
33. Colucci WS, Elkayam U, Horton DP, et al: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000 Jul 27; 343(4): 246-53.
34. Colucci WS, Packer M, Bristow MR, et al: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996 Dec 1; 94(11): 2800-6.
35. Colucci WS, Sonnenblick EH, Adams KF, et al: Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators. J Am Coll Cardiol 1993 Oct; 22(4 Suppl A): 113A-118A.
36. Crozier I, Ikram H, Awan N, et al: Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation 1995 Feb 1; 91(3): 691-7.
37. Dries DL, Exner DV, Gersh BJ, et al: Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ven. J Am Coll Cardiol 1998 Sep; 32(3): 695-703.
38. Dunkman WB, Johnson GR, Carson PE, et al: Incidence of thromboembolic events in congestive heart failure. The V- HeFT VA Cooperative Studies Group. Circulation 1993 Jun; 87(6 Suppl): VI94-101.
39. Exercise Standards. A statement for health professionals from the American Heart Association. Special Report. Circulation. 1990;82(6):2291–2292.
40. Flaker GC, Blackshear JL, McBride R, et al: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992 Sep; 20(3): 527-32.
41. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, et al: Effect of direct vasodilation with hydralazine versus angiotensin- converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol 1992 Mar 15; 19(4): 842-50.
42. 34. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double–blind, placebo–controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–788
43. Francis GS, Benedict C, Johnstone DE, et al: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990 Nov; 82(5): 1724-9.
44. Francis GS, Cohn JN, Johnson G, et al: Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993 Jun; 87(6 Suppl): VI40-8.
45. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J. 2001;22:1852–923.
46. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995 May 10; 273(18): 1450-6.
47. Gottlieb SS, Fisher ML, Kjekshus J. Tolerability of beta-blocker intitiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) // Circulation. – 2002. – Vol. 105: 1182-1188.
48. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left–ventricular systolic function intolerant to angiotensin–converting–enzyme inhibitors: the CHARM–Alternative trial. Lancet. 2003;362:772–6.
49. Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Sydney (Australia): National Heart Foundation of Australia. 2006, 79 p.
50. Guidelines for the diagnosis and treatment of chronic heart failure. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology / W.J. Remme, K. Swedberg (Co-Chairmen) // Europ. Heart J. – 2001. – Vol. 22:1527-1560.
51. Guidelines for the diagnosis and treatment of Chronic Heart Failure: full text (update 2005) The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology (European Heart Journal doi:10.1093/eurheartj/ehi205).
52. Hjalmarson A, Goldstein S, Fagerberg B, et al, for the MERIT–HF Study Group. Effects of controlled–release metoprolol on total mortality, hospitalizations, and well–being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT–HF). JAMA. 2000;283:1295–302.
53. Jaganmohan S, Khurana V. Statins improve survival in patients with congestive heart failure: a study on 32000 US veterans. JACC. 2005;45(suppl A):854–7 250. Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. The Eur J Heart Fail. 2005;7:1059–1069.
54. Jones CG, Cleland JG. Meeting report: the LIDO, HOPE, MOXCON and WASH studies: Heart Outcomes Prevention Evaluation. The Warfarin/Aspirin Study of Heart Failure. Eur J Heart Fail. 1999;1:425–431.
55. Kleber FX, Niemцller L. – Long–term survival in the Munich Mild Heart Failure Trial (MHFT). Am J Cardiol. 1993;71(13):1237–1239
56. Kostis JB, Davis BR, Cutler J, et al, for the SHEP Cooperative Research Group. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212–216.
57. Krum H., Roecker F.B., Monacsi P. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study // J. A. M. A. – 2003. – Vol. 289: 712-718.
58. Major outcomes in high–risk hypertensive patients randomized to angiotensin–converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid–Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.
59. Management of chronic heart failure. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN). 2007, 53 p.
60. Massie B. – Final results of the warfarin and antiplatelet trial in chronic heart failure (WATCH): a randomized comparison of warfarin, aspirin and clopidogrel. J Card Fail. 2004;10:101–112.
61. McKelvie RS, Yusuf S, Pericak D, et al: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999 Sep 7; 100(10): 1056-64.
62. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin–convertingenzyme inhibitors: the CHARM–Added trial. Lancet. 2003;362:767–71.
63. McMurray et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice), copyright (2001), with permission from European Society of Cardiology. European Journal of Heart Failure 2001, 3, 495–502.
64. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronicheart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) // Lancet. – 1999. – Vol. 353: 2001-2007.
65. Mills RM, LeJemtel TH, Horton DP, et al: Sustained hemodynamic effects of an infusion of nesiritide (human b- type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999 Jul; 34(1): 155-62.
66. O’Connor CM, Carson PE, Miller AB et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol. 1998;82(7):881–7.
67. Packer M, Carver JR, Rodeheffer RJ, et al: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991 Nov 21; 325(21): 1468-75.
68. Packer M, Fowler MB, Roecker EB, et al: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002 Oct 22; 106(17): 2194-9.
69. Packer M, O’Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335(15):1107–14.
70. Packer M, Poole-Wilson PA, Armstrong PW, et al: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999 Dec 7; 100(23): 2312-8.
71. Patterson JH, Adams KF Jr, Applefeld MM, et al: Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy 1994 Sep-Oct; 14(5): 514-21.
72. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992 Sep 3; 327(10): 669-77.
73. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 Sep 2; 341(10): 709-17.
74. Pitt B, Poole-Wilson PA, Segal R, et al: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000 May 6; 355(9215): 1582-7.
75. Poole–Wilson PA, Uretsky BF, Thygesen K et al. Mode of death in heart failure: findings from the ATLAS trial. Heart. 2003;Vol. 89:p. 42–48
76. Rector TS, Johnson G, Dunkman WB, et al: Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993 Jun; 87(6 Suppl): VI71-7.
77. Rich MW, McSherry F, Williford WO: Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 2001 Sep; 38(3): 806-13.